Aridis Pharmaceuticals

About:

Aridis is a biopharmaceutical company focused on the development of novel, differentiated therapies for infectious diseases.

Website: http://aridispharma.com/

Twitter/X: Aridis_Pharma

Top Investors: Bill & Melinda Gates Foundation, Cystic Fibrosis Foundation, EFung Capital

Description:

Aridis Pharmaceuticals discovers and develops anti-infectives to be used as add-on treatments to standard-of-care antibiotics. The company is utilizing its proprietary ʎPEXTM and MabIgX technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome infection and to rapidly manufacture monoclonal antibodies (mAbs) for the therapeutic treatment of critical infections. These mAbs are already of human origin and functionally optimized for high potency by the donor's immune system; hence, they technically do not require genetic engineering or further optimization to achieve full functionality.

Total Funding Amount:

$81.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Jose, California, United States

Founded Date:

2003-01-01

Contact Email:

patzere(AT)aridispharma.com

Founders:

Eric Patzer, Vu L. Truong

Number of Employees:

11-50

Last Funding Date:

2023-03-14

IPO Status:

Public

Industries:

© 2025 bioDAO.ai